Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients (Q43146817)

14 November 2017

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients (English)

1 reference

diffuse large B-cell lymphoma

14 November 2017

1 reference

1 reference

5

Mats Jerkeman

1 reference

14 November 2017

Sari Riihijärvi

1

1 reference

14 November 2017

Satu Koivula

2

1 reference

14 November 2017

Heidi Nyman

3

1 reference

14 November 2017

Karin Rydström

4

1 reference

14 November 2017

Sirpa Leppä

6

1 reference

14 November 2017

26 February 2010

1 reference

14 November 2017

1 reference

14 November 2017

23

1 reference

14 November 2017

5

1 reference

14 November 2017

686-693

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2010.43

14 November 2017

0 references

cites work

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with CHOP and rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Stromal gene signatures in large-B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Protein kinase C and other diacylglycerol effectors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

PKC-beta II expression has prognostic impact in nodal diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Hematology: germinal center or nongerminal center DLBCL?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

inferred from DOI database lookup

7 January 2021

based on heuristic

Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

inferred from DOI database lookup

7 January 2021

based on heuristic

Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2010.43

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/MODPATHOL.2010.43

1 reference

Dimensions Publication ID

14 November 2017

0 references

1 reference